Indicators for safe withdrawal of nucleos(t)ide analogues antivirals for chronic hepatitis B
LIU Lu-jie
LIU Yan
LIU Xin-guang
XU Dong-ping
Abstract：One of the difficulties in chronic hepatitis B (CHB) treatment is to safely withdraw drugs or determine the endpoint of antiviral therapy. At present, serum HBV DNA, HBeAg/anti-HBe, HBsAg/anti-HBs and anti-HBc are major indicators for evaluating the treatment effect of CHB, and persistent HBsAg loss is considered as the standard of drug withdrawal. However, the proportion of serum HBsAg loss is very low and it's difficult to achieve clinical cure or functional cure. The indicators with potential value for evaluation for drug withdrawal in CHB patients, including intrahepatic HBV cccDNA, serum HBcrAg, and serum HBV RNA are developed in recent years. This paper aims to overview the progress of these indicators.
Keywords：chronic hepatitis Bnucleos(t)ide analoguesantiviral treatmentsafe discontinuationindicators
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 203-208 )